多西环素和IGF-1作为OA疾病修饰的协同组合疗法
Arijit Bhattacharjee1, Saptomee Chakraborty1, Praganesh Kumar2
1Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India; The Mehta Family Center for Engineering in Medicine, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|December 16, 2025
概括
这项研究探讨了使用Dox和IGF-1治疗骨关节炎 (OA) 的联合治疗方法. 治疗协同减少了炎症和矩阵降解,为OA疾病修饰提供了一个有希望的方法.
科学领域:
- 生物医学工程 生物医学工程
- 分子生物学分子生物学
- 类风湿病学 类风湿病学
背景情况:
- 骨关节炎 (OA) 是一种普遍存在的,使人虚弱的关节疾病,导致严重的疼痛,残疾和社会经济负担.
- 目前的骨关节炎治疗提供症状缓解,但不会改变疾病的进展,突出显示了对疾病修饰性骨关节炎药物 (DMOADs) 的需求.
- 关节炎的多因素病原体对开发有效的DMOADs提出了挑战.
研究的目的:
- 为了研究一种新的组合疗法,针对可代谢和可代谢过程,以改善骨关节炎.
- 评估Dox和IGF-1在临床前模型和人类软骨实验室中对OA病变的协同作用.
主要方法:
- 利用Dox和IGF-1的联合疗法来准OA中的可代谢和可合成途径.
- 评估了组合疗法对母体降解,炎症和母体保留在体外OA软骨模型 (山羊和人类) 的影响.
- 研究了潜在的分子机制,包括NF-κB和c-JUN/JNK信号通路.
主要成果:
- 多克斯和IGF-1联合疗法证明了OA发病的协同抑制,减少了矩阵降解和炎症.
- 治疗增强了矩阵保留,并在人类OA软骨扩展物中得到了验证,表明了转化潜力.
- 从机制上讲,该组合抑制了NF-κB介导的炎症,并减少了c-JUN/JNK通路的激活,改善了类似于OA的疾病.
结论:
- 多克斯和IGF-1的组合显示出作为修饰骨关节炎疾病的治疗策略的显著潜力.
- 这种方法解决了对可以改变OA进展超出症状缓解的治疗方法的关键未满足需求.
- 对这种组合治疗的进一步研究可能会导致骨关节炎的改善管理和减少患者残疾.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293